Publikationen, an denen er mitarbeitet Carlos de las Cuevas Castresana (51)

2024

  1. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)

    Schizophrenia Research, Vol. 268, pp. 165-174

  2. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 53-59

  3. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 60-65

  4. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature

    Expert Opinion on Drug Safety

  5. Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database

    Schizophrenia Research, Vol. 268, pp. 118-130

  6. Investigating in VigiBase over 6000 cases of pneumonia in clozapine-treated patients in the context of the literature: focus on high lethality and the association with aspiration pneumonia

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 20, Núm. 8, pp. 857-871

  7. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK

    Schizophrenia Research, Vol. 268, pp. 175-188

2023

  1. Escaping the Long Shadow Cast by Agranulocytosis: Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom

    Journal of Clinical Psychopharmacology, Vol. 43, Núm. 3, pp. 239-245

  2. Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 19, Núm. 2, pp. 57-74

2022

  1. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

    Pharmacopsychiatry, Vol. 55, Núm. 2, pp. 73-86

  2. Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase

    Expert Review of Clinical Pharmacology, Vol. 15, Núm. 1, pp. 65-78

  3. Clozapine and the risk of haematological malignancies

    The Lancet Psychiatry

  4. Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries

    Revista de Psiquiatria y Salud Mental, Vol. 15, Núm. 4, pp. 238-250

  5. Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 18, Núm. 11, pp. 715-727

  6. Erratum: Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels (Pharmacopsychiatry (2022) 55 2 (73-86))

    Pharmacopsychiatry

  7. Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 18, Núm. 9, pp. 541-553

2021

  1. The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase

    Psychological Medicine

2020

  1. Data From the World Health Organization's Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions

    Schizophrenia bulletin, Vol. 46, Núm. 1, pp. 1-3

  2. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics

    World Psychiatry

2017

  1. Seguridad vial y toxicidad conductual por psicofármacos

    Salud(i)Ciencia, Vol. 22, Núm. 4, pp. 379-382